State Street
ACTU

State Street’s Actuate Therapeutics ACTU Stock Holding History

State Street’s Portfolio ACTU Stock Details ACTU Fund Activity
Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake 		Trade Value Portfolio Weight Portfolio Position
2026
Q1 		$181K Buy
66,030
+9,740
+17% +$40.4K ﹤0.01% 3906
2025
Q4 		$344K Buy
56,290
+6,395
+13% +$43.9K ﹤0.01% 3776
2025
Q3 		$334K Buy
49,895
+18,481
+59% +$134K ﹤0.01% 3755
2025
Q2 		$192K Buy
+31,414
New +$274K ﹤0.01% 3850

Other funds holding ACTU

BCM
BIOS Capital Management Fort Worth, Texas $52.9M AUM 30.51% 1-Year Est. Return
VC
Voss Capital Houston, Texas $1.88B AUM 1.03% 1-Year Est. Return
BlackRock
BlackRock New York $5.72T AUM 30.48% 1-Year Est. Return
VCM
Vanguard Capital Management Malvern, Pennsylvania $4.04T AUM
Geode Capital Management
Geode Capital Management Boston, Massachusetts $1.61T AUM 30.72% 1-Year Est. Return
CCM
Connective Capital Management Palo Alto, California $121M AUM 39.82% 1-Year Est. Return
PVM
Palogic Value Management Dallas, Texas $237M AUM 5.37% 1-Year Est. Return
Northern Trust
Northern Trust Chicago, Illinois $757B AUM 28.64% 1-Year Est. Return
TCBWMS
Texas Capital Bank Wealth Management Services Dallas, Texas $1.68B AUM 21.72% 1-Year Est. Return
VFT
Vanguard Fiduciary Trust Malvern, Pennsylvania $396B AUM

State Street's ACTU Position: Q1 2026 in Review

State Street increased its Actuate Therapeutics (ACTU) stake by 17% in Q1 2026, buying an estimated $40.4K and bringing the position to 66,030 shares worth $181K. The position accounts for ﹤0.01% of the portfolio, ranked #3906.

State Street first reported a position in ACTU in Q2 2025 and has held it in 4 quarters since. The position peaked at $344K in Q4 2025. 61 funds tracked by Wall St. Rank hold ACTU as of Q1 2026.

  • State Street held 66,030 shares of Actuate Therapeutics worth $181K as of Q1 2026.
  • State Street bought 9,740 Actuate Therapeutics shares in Q1 2026, an estimated $40.4K.
  • Actuate Therapeutics made up ﹤0.01% of State Street's portfolio in Q1 2026, its #3906 holding.
  • State Street first reported a position in Actuate Therapeutics in Q2 2025 and has held it in 4 quarters since.
  • State Street's Actuate Therapeutics position peaked at $344K in Q4 2025.
  • 61 funds tracked by Wall St. Rank held Actuate Therapeutics as of Q1 2026.

Based on State Street's 13F filing for Q1 2026, filed 15 May 2026.